Amgen's Rare Autoimmune Disease Candidate Shows Improvement In Disease Burden In Treating Sjögren's Syndrome
Portfolio Pulse from Vandana Singh
Amgen Inc has released new data from its Phase 2 study of dazodalibep for Sjögren's syndrome, a chronic autoimmune disorder. The study showed that patients who transitioned from placebo to dazodalibep experienced an improvement in their disease activity and symptoms. The drug was generally safe and well tolerated.
November 08, 2023 | 4:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amgen's Phase 2 study of dazodalibep for Sjögren's syndrome showed positive results, which could potentially boost the company's stock in the short term.
The positive results from the Phase 2 study of dazodalibep for Sjögren's syndrome could potentially lead to increased investor confidence in Amgen, which could in turn lead to a short-term increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100